Lloyd Advisory Services LLC. Has $267,000 Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Lloyd Advisory Services LLC. reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 86.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 502 shares of the medical research company’s stock after selling 3,154 shares during the quarter. Lloyd Advisory Services LLC.’s holdings in Thermo Fisher Scientific were worth $267,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Northwest Financial Advisors purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $29,000. Cape Investment Advisory Inc. raised its position in Thermo Fisher Scientific by 52.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company’s stock worth $40,000 after acquiring an additional 26 shares during the period. Raleigh Capital Management Inc. raised its position in Thermo Fisher Scientific by 49.1% in the third quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after acquiring an additional 27 shares during the period. Cedar Mountain Advisors LLC raised its position in Thermo Fisher Scientific by 107.0% in the fourth quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after acquiring an additional 46 shares during the period. Finally, Frazier Financial Advisors LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth about $49,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. HSBC boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Robert W. Baird reduced their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. JPMorgan Chase & Co. boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Evercore ISI boosted their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $605.31.

Get Our Latest Stock Report on TMO

Thermo Fisher Scientific Stock Up 0.9 %

Shares of Thermo Fisher Scientific stock traded up $5.22 during trading on Friday, hitting $567.98. The company’s stock had a trading volume of 2,106,711 shares, compared to its average volume of 1,263,763. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The company has a fifty day simple moving average of $575.32 and a two-hundred day simple moving average of $551.71. The company has a market capitalization of $216.81 billion, a PE ratio of 36.43, a P/E/G ratio of 2.63 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date is Friday, June 14th. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders have sold a total of 22,000 shares of company stock valued at $12,839,780 in the last 90 days. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Read More

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.